ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin lymphoma(HL). Preliminary results of HD2000 GISL trial

被引：0
|
作者：
Federico, M. [1 ]
Luminari, S. [1 ]
Olio, M. Dell' [2 ]
Merli, F. [3 ]
Brugiatelli, M. [4 ]
Stelitano, C. [5 ]
Mammi, C. [1 ]
Musso, M. [6 ]
Baldini, L. [7 ]
Marcheselli, L. [1 ]
Gobbi P G, P. G. [8 ]
机构：
[1] Univ Modena & Reggio Emilia, Dipartimento Oncol & Ematol, Modena, Italy
[2] AO Casa Sollievo Sofferenza, San Giovanni Rotondo, FG, Italy
[3] AOS Maria Nuova, Reggio Emilia, Italy
[4] AO Papardo, Messina, Italy
[5] AO Bianchi Melacrino Morelli, Reggio Di Calabria, Italy
[6] AO La Maddalena, Palermo, Italy
[7] Osped Maggiore, IRCCS, Milan, Italy
[8] Univ Pavia, Med Clin, I-27100 Pavia, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [1] ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
    Federico, Massimo
    Luminari, Stefano
    Iannitto, Emilio
    Polimeno, Giuseppe
    Marcheselli, Luigi
    Montanini, Antonella
    La Sala, Antonio
    Merli, Francesco
    Stelitano, Caterina
    Pozzi, Samantha
    Scalone, Renato
    Di Renzo, Nicola
    Musto, Pellegrino
    Baldini, Luca
    Cervetti, Giulia
    Angrilli, Francesco
    Mazza, Patrizio
    Brugiatelli, Maura
    Gobbi, Paolo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 805 - 811
  • [2] Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: results from the hd2000 GISL trial
    Morabito, Fortunato
    Hohaus, Stefan
    Mammi, Corrado
    Marcheselli, Luigi
    Gentile, Massimo
    Merli, Francesco
    Montanini, Antonella
    Stelitano, Caterina
    La Sala, Antonio
    Scalone, Renato
    Voso, Maria Teresa
    Luminari, Stefano
    Iannitto, Emilio
    Gobbi, Paolo
    Federico, Massimo
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 406 - 410
  • [3] PET-guided treatment with BrECADD vs. BEACOPP for advanced stage Hodgkin Lymphoma: Results from the Phase III GHSG HD21 trial
    Dietlein, Markus
    Ferdinandus, Justin
    Fuchs, Michael
    Eich, Hans
    Baues, Christian
    Kobe, Carsten
    Borchmann, Peter
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [4] ABVD vs. STANFORD V (SV) vs. MOPP-EBV-CAD (MEC) in advanced Hodgkin's lymphoma. Final results of the IIL HD9601 randomized trial.
    Federico, M
    Levis, A
    Luminari, S
    Chisesi, T
    Marcheselli, L
    Goldaniga, M
    Vitolo, U
    Neri, S
    Brugiatelli, M
    Gobbi, PG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 559S - 559S
  • [5] Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
    Merli, Francesco
    Luminari, Stefano
    Gobbi, Paolo G.
    Cascavilla, Nicola
    Mammi, Caterina
    Ilariucci, Fiorella
    Stelitano, Caterina
    Musso, Maurizio
    Baldini, Luca
    Galimberti, Sara
    Angrilli, Francesco
    Polimeno, Giuseppe
    Scalzulli, Potito Rosario
    Ferrari, Angela
    Marcheselli, Luigi
    Federico, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (11) : 1175 - +
  • [6] ABVD vs. radiotherapy in early stage Hodgkin's lymphoma A critical look at the NCIC HD.6 trial
    Wenz, F.
    Abo-Madyan, Y.
    Welzel, G.
    Giordano, F. A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 649 - 652
  • [7] Randomised controlled trial of ABVD vs. two multi-drug regimens (MDRs) for advanced Hodgkin's lymphoma (HL): Initial results of UKLG LY09 (ISRCTN97144519).
    Hancock, B
    Radford, J
    Cullen, MH
    Walewski, J
    Sydes, MR
    Ryder, D
    Smith, P
    Clawson, S
    Stenning, SP
    Johnson, PM
    BRITISH JOURNAL OF CANCER, 2004, 91 : S1 - S1
  • [8] PROGNOSTIC SIGNIFICANCE OF GLUTATHIONE-S-TRANSFERASE (GST) GENOTYPES IN PATIENTS WITH ADVANCED HODGKIN' DISEASE (HD) ENROLLED IN THE HD2000 GISL TRIAL
    Gentile, M.
    Mammi, C.
    Marcheselli, L.
    Merli, F.
    Cascavilla, N.
    Luminari, S.
    Stelitano, C.
    Musso, M.
    Iannitto, E.
    Angrilli, F.
    Petrini, M.
    Riezzo, A.
    Romito, S.
    Quarta, G.
    Partesotti, G.
    Molica, S.
    Fracasso, A.
    Polimeno, G.
    Lombardo, M.
    Russo, M.
    Ilariucci, F.
    La Sala, A.
    Pozzi, S.
    Callea, V.
    Scalone, R.
    Lagana, C.
    Federico, M.
    Morabito, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 246 - 247
  • [9] CNOP vs. CNOP-Rituximab vs. Rituximab alone as first-line therapy for indolent non-Hodgkin lymphoma (INHL): Preliminary results.
    Baltasar, SA
    Tripp, FV
    Baez, ED
    Rivas, S
    Duque, J
    Garces, O
    Rodriguez, P
    Rubio, B
    Delgado, JL
    Solis, L
    Batista, B
    Ignacio, G
    Castillo, H
    Cervantes, G
    Talavera, J
    Rubio-Borja, ME
    BLOOD, 2003, 102 (11) : 304B - 305B
  • [10] Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi
    Merli, Francesco
    Luminari, Stefano
    Mammi, Caterina
    Cascavilla, Nicola
    Bari, Alessia
    Stelitano, Caterina
    Scalone, Renato
    Baldini, Luca
    Angrilli, Francesco
    Polimeno, Giuseppe
    Gobbi, Paolo G.
    Cervetti, Giulia
    Ilariucci, Fiorella
    Ruffini, Alessia
    Marcheselli, Luigi
    Federico, Massimo
    BLOOD, 2014, 124 (21)
12345